Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX26 plus serplulimab in advanced solid tumors
NCT05400265Phase 1Completed
- Sponsor
- Henlius
- Start
- Jul 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of hlx26 in solid tumor (3 arms), sponsored by Henlius. Primary endpoints: Dose-Limiting Toxicity at 21 days and Maximum Tolerated Dose at 21 days. Started Jul 2022; status: completed.
02
Drugs
hlx26
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05400265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05400265.